Analysts believe the key question is whether India can be exempted from the pharma tariffs, given the better relationship ...

Global drugmakers' stocks dropped across the board after US President Donald Trump reiterated plans for a "major" tariff on ...

"If India counters with its own tariffs, it could disrupt supply chains, increase costs, and slow market expansion for both ...

US President Donald Trump’s sudden, shocking 90-day pause on his so-called “reciprocal” tariffs (they were not reciprocal) ...

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and onl ...

The company has also launched a new technology and innovation site in Hyderabad, India, named Amgen India, with a $200 million investment plan through 2025. This site aims to enhance Amgen’s ...

Analysts warn that these tariffs could lead to higher production costs, reduced profitability, and even drug shortages. As Trump’s tariff threats loom, investors are left questioning whether to hold ...

Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from ...

Drugmaker Amgen to invest $200 million in India site, CEO says U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...

Pharmaceutical (TADAWUL:2070) stocks saw brief relief Thursday after U.S. President Donald Trump left drug products off the list of newly announced tariffs. However, industry leaders and analysts ...

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies ...